2019冠状病毒病的凝血功能障碍
本文为叙述性综述,通过检索PubMed汇总COVID-19相关凝血功能障碍与血栓栓塞的文献。COVID-19与高 prevalence 的凝血功能障碍和静脉血栓栓塞症相关,可能促进呼吸恶化。感染初期D-二聚体和纤维蛋白原升高,而活化部分凝血活酶时间、凝血酶原时间和血小板计数常相对正常;D-二聚体升至正常上限3倍可能触发静脉血栓栓塞症筛查。目前推荐所有住院患者使用低分子肝素进行血栓预防,特定临床情况需增加治疗性抗凝。
要点
- 所有住院COVID-19患者目前推荐使用低分子肝素进行血栓预防。
- D-二聚体水平升至正常上限3倍可能触发静脉血栓栓塞症筛查。
- 感染初期D-二聚体和纤维蛋白原升高,活化部分凝血活酶时间、凝血酶原时间和血小板计数常相对正常。
- 异常凝血指标与不良结局相关,可能需要辅助抗血栓干预,监测凝血变量很重要。
- COVID-19凝血障碍兼具微血管病和局部血栓形成,以及导致大血管血栓和主要血栓栓塞并发症(包括肺栓塞)的全身性凝血缺陷。
适用人群与场景
- 住院的COVID-19患者,包括重症监护病房的危重住院患者。
诊断标准与关键阈值
- D-二聚体水平升至正常上限3倍可能触发静脉血栓栓塞症筛查。
处置流程与药物剂量
- 所有住院患者目前推荐使用低分子肝素进行血栓预防。
- 特定临床情况下增加治疗性抗凝。
- 监测D-二聚体和纤维蛋白原水平。
- 监测凝血变量,因异常凝血指标与不良结局相关并可能需要辅助抗血栓干预。
红旗征与不能漏的情况
- 静脉血栓栓塞症,包括重症住院患者的肺栓塞。
- 呼吸恶化,可能由凝血功能障碍和静脉血栓栓塞症促发。
研究设计与关键结果
- 叙述性综述,通过PubMed检索COVID-19、SARS、急性呼吸窘迫综合征、冠状病毒、凝血障碍、血栓和抗凝剂相关文献。
- COVID-19与高 prevalence 的凝血功能障碍和静脉血栓栓塞症相关,可能促进呼吸恶化。
- 感染初期D-二聚体和纤维蛋白原水平升高,而活化部分凝血活酶时间、凝血酶原时间和血小板计数常相对正常。
- 凝血障碍的病因复杂,被认为是宿主防御机制与凝血系统特定相互作用的结果;虽类似弥散性血管内凝血和血栓性微血管病,但特征明显不同。
证据类型、等级与局限
- 证据类型:叙述性综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 所有住院COVID-19患者应接受低分子肝素血栓预防。
- D-二聚体升至正常上限3倍时可能需筛查静脉血栓栓塞症。
- 监测D-二聚体和纤维蛋白原水平,异常凝血指标与不良结局相关。
- 特定临床情况下增加治疗性抗凝。
指南或共识出处
- Crit Care Med 发表的叙述性综述《Coagulopathy of Coronavirus Disease 2019》。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Recent studies have reported a high prevalence of thrombotic events in coronavirus disease 2019. However, the significance of thromboembolic complications has not been widely appreciated. The purpose of this review is to provide current knowledge of this serious problem.
DESIGN: Narrative review.
DATA SOURCES: Online search of published medical literature through PubMed using the term "COVID-19," "SARS," "acute respiratory distress syndrome," "coronavirus," "coagulopathy," "thrombus," and "anticoagulants."
STUDY SELECTION AND DATA EXTRACTION: Articles were chosen for inclusion based on their relevance to coagulopathy and thrombosis in coronavirus disease 2019, and anticoagulant therapy. Reference lists were reviewed to identify additional relevant articles.
DATA SYNTHESIS: Coronavirus disease 2019 is associated with a strikingly high prevalence of coagulopathy and venous thromboembolism that may contribute to respiratory deterioration. Monitoring coagulation variables is important, as abnormal coagulation tests are related to adverse outcomes and may necessitate adjuvant antithrombotic interventions. In the initial phase of the infection, D-dimer and fibrinogen levels are increased, while activated partial prothrombin time, prothrombin time, and platelet counts are often relatively normal. Increased D-dimer levels three times the upper limit of normal may trigger screening for venous thromboembolism. In all hospitalized patients, thromboprophylaxis using low-molecular-weight heparin is currently recommended. The etiology of the procoagulant responses is complex and thought to be a result of specific interactions between host defense mechanisms and the coagulation system. Although the coagulopathy is reminiscent of disseminated intravascular coagulation and thrombotic microangiopathy, it has features that are markedly distinct from these entities.
CONCLUSIONS: Severe acute respiratory syndrome coronavirus 2/coronavirus disease 2019 frequently induces hypercoagulability with both microangiopathy and local thrombus formation, and a systemic coagulation defect that leads to large vessel thrombosis and major thromboembolic complications, including pulmonary embolism in critically ill hospitalized patients. D-dimers and fibrinogen levels should be monitored, and all hospitalized patients should undergo thromboembolism prophylaxis with an increase in therapeutic anticoagulation in certain clinical situations.
参考来源
- Iba T, Levy JH, Levi M, et al. Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020. PMID: 32467443. doi:10.1097/CCM.0000000000004458
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。